84 related articles for article (PubMed ID: 20873967)
1. Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer.
Svendsen MN; Brünner N; Christensen IJ; Ytting H; Bentsen C; Lomholt AF; Nielsen HJ
Scand J Clin Lab Invest; 2010 Nov; 70(7):503-11. PubMed ID: 20873967
[TBL] [Abstract][Full Text] [Related]
2. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
[TBL] [Abstract][Full Text] [Related]
3. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during long-term follow-up of colorectal cancer patients.
Roumen RM; Slooter GD; Croiset van Uchelen FA; Huib LV
Dis Colon Rectum; 2005 May; 48(5):1070-5. PubMed ID: 15785896
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Bocci G; Man S; Green SK; Francia G; Ebos JM; du Manoir JM; Weinerman A; Emmenegger U; Ma L; Thorpe P; Davidoff A; Huber J; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Sep; 64(18):6616-25. PubMed ID: 15374976
[TBL] [Abstract][Full Text] [Related]
9. Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.
Nakayama Y; Sako T; Shibao K; Onitsuka K; Nagashima N; Hirata K; Nagata N; Itoh H
Anticancer Res; 2000; 20(6A):4097-102. PubMed ID: 11131678
[TBL] [Abstract][Full Text] [Related]
10. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.
Kirman I; Belizon A; Balik E; Feingold D; Arnell T; Horst P; Kumara S; Cekic V; Jain S; Nasar A; Whelan RL
Eur J Surg Oncol; 2007 Dec; 33(10):1169-76. PubMed ID: 17512160
[TBL] [Abstract][Full Text] [Related]
11. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
[TBL] [Abstract][Full Text] [Related]
12. Circulating vascular endothelial growth factor in patients with colorectal cancer.
Fujisaki K; Mitsuyama K; Toyonaga A; Matsuo K; Tanikawa K
Am J Gastroenterol; 1998 Feb; 93(2):249-52. PubMed ID: 9468253
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
14. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients.
Famulski W; Sulkowska M; Wincewicz A; Kedra B; Pawlak K; Zalewski B; Sulkowski S; Koda M; Baltaziak M
Neoplasma; 2006; 53(1):43-8. PubMed ID: 16416012
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients.
Dymicka-Piekarska V; Guzinska-Ustymowicz K; Kuklinski A; Kemona H
Thromb Res; 2012 Apr; 129(4):e47-50. PubMed ID: 22209338
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Kim JY; Bae BN; Kwon JE; Kim HJ; Park K
APMIS; 2011 Jul; 119(7):449-59. PubMed ID: 21635552
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
White JD; Hewett PW; Kosuge D; McCulloch T; Enholm BC; Carmichael J; Murray JC
Cancer Res; 2002 Mar; 62(6):1669-75. PubMed ID: 11912138
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer.
Nakayama Y; Sako T; Shibao K; Okazaki K; Rempo N; Onitsuka K; Minagawa N; Akahane K; Nagashima N; Nagata N; Itoh H
Anticancer Res; 2002; 22(4):2437-42. PubMed ID: 12174940
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
